Dr. Nitin Pal Kalia | Immunology and Microbiology | Best Researcher Award

Dr. Nitin Pal Kalia | Immunology and Microbiology | Best Researcher Award

Dr. Nitin Pal Kalia, Assistant Professor, National Institute of Pharmaceutical Education and Research Hyderabad, India

๐ŸŒŸ Dr. Nitin Pal Kalia ๐ŸŒŸ, an esteemed Assistant Professor at the National Institute of Pharmaceutical Education and Research, Hyderabad, India, is renowned for his groundbreaking research in Immunology and Microbiology ๐Ÿงฌ๐Ÿ”ฌ. His innovative work has earned him the prestigious Best Researcher Award ๐Ÿ†, recognizing his significant contributions to the scientific community ๐ŸŒ. Dr. Kalia’s research focuses on understanding the immune system’s complexities and developing novel therapeutic strategies to combat infectious diseases ๐Ÿ’‰๐Ÿฆ . His dedication to advancing pharmaceutical education and research has made him a prominent figure in his field ๐Ÿ“š๐ŸŽ“.

๐Ÿ‘ฉโ€๐ŸŽ“ Profile

Googlescholar, Orcid

๐Ÿ“šย  Education

๐ŸŽ“ Dr. Nitin Pal Kalia earned his Ph.D. in Biotechnology from the Indian Institute of Integrative Medicine, Jammu, India, under the guidance of Dr. Inshad Ali Khan, Sr. Principal Scientist, from October 2007 to January 2014 ๐Ÿงช. He previously completed his M.Sc. in Biotechnology at Guru Nanak Dev University, Amritsar, Punjab, India, from June 2004 to May 2006, after qualifying the CEEB examination conducted by JNU ๐Ÿงฌ. Dr. Kalia’s academic journey reflects his dedication to the field of Clinical Microbiology and Biotechnology ๐Ÿ“š๐Ÿ”ฌ.

๐Ÿ”ฌ Research Experience

๐Ÿ“š Dr. Nitin Pal Kalia is an esteemed Assistant Professor at NIPER, Hyderabad, Telangana, India, since February 4, 2021. ๐ŸŒŸ Previously, he was honored with the Ramalingaswami Fellowship by the Department of Biotechnology, serving at CSIR-IIIM Jammu from August 16, 2019, to February 1, 2021. ๐ŸŽ“ He was a Research Fellow at Lee Kong Chian School of Medicine, NTU Singapore, from October 16, 2015, to August 15, 2019. ๐ŸŒ Dr. Kalia also gained valuable experience as a Visiting Fellow at NIAID-NIH Bethesda, USA, from May 16, 2014, to July 31, 2015. ๐ŸŒŸ๐Ÿ‘

๐ŸŽ“ Trainings

Dr. Nitin Pal Kalia has impressive experience in biotech research. From February to July 2007, he worked as a trainee on a project titled โ€œCloning and recombinant expression of Rhabdovirus antigens for vaccine developmentโ€ at Bharat Biotech International Private Limited in Hyderabad under the Biotech Industrial Training Program sponsored by the Department of Biotechnology, Govt. of India ๐Ÿงฌ๐Ÿ’‰. Additionally, from June to July 2005, he was a trainee on a project entitled โ€œIdentifying Bacterial Diversity in Natural Environment: a molecular phylogenetic approachโ€ at IHBT-CSIR in Palampur, Himachal Pradesh ๐ŸŒฟ๐Ÿ”ฌ.

๐Ÿ† Accomplishments

Dr. Nitin Pal Kalia has a distinguished record in biosafety and research. ๐Ÿ† He was awarded the Ramalingaswami Re-entry Fellowship (2017-2018) by DBT, India. His expertise includes BSL-3 training from the National University of Singapore (2016) and NIH USA (2014 & 2015). ๐Ÿงช He completed hands-on training on laboratory animal care with A*Star Singapore (2015) and holds the IIIM-CSIR award for novel tuberculosis scaffolds (2013). ๐Ÿฆ  Dr. Kalia also received the ICMR-Senior Research Fellowship for his work on Staphylococcus aureus (2010) and was sponsored by DBT for industrial training (2007). ๐Ÿงฌ He qualified JNU’s Biotechnology Entrance Exam in 2004. ๐ŸŽ“

๐Ÿ”ฌ Doctoral Research & Post-Doctoral Research

Dr. Nitin Pal Kalia focuses on innovative approaches to combat drug-resistant Mycobacterium tuberculosis. His research explores targeting terminal oxidases and cell wall synthesis. Key findings include the use of Q203 to inhibit the respiratory cytochrome bc1 complex and ongoing efforts to identify potent inhibitors for the bd-oxidase. At NIH, he evaluated new chemical entities, profiling them against resistant MTb mutants. During his Ph.D., he discovered capsaicin as an inhibitor of the NorA efflux pump, significantly reducing the invasiveness of Staphylococcus aureus in macrophages. ๐Ÿ’Š๐Ÿ”ฌ๐Ÿฆ ๐Ÿ”

๐Ÿ”ง Workshops

๐ŸŒŸ Dr. Nitin Pal Kalia has participated in significant workshops, enhancing his expertise in biotechnology and regulatory toxicology. He attended a workshop on โ€œManagement of IPR in Biotechnologyโ€ in Hyderabad, sponsored by the Department of Biotechnology, Government of India (April 26-27, 2007) ๐ŸŒฑ๐Ÿ”ฌ. Additionally, he engaged in an online national workshop on โ€˜Role of Regulatory Toxicology and Good Laboratory Practice (GLP) in Drug Discovery and Developmentโ€™ conducted by NIPER, Hyderabad (August 27-28, 2020) ๐Ÿ’ป๐Ÿ’Š. These experiences have enriched his knowledge and professional growth in these crucial fields. ๐Ÿ“šโœจ

๐Ÿ“ Abstracts presented in conferences

Dr. Nitin Pal Kalia has made significant contributions to the field of medicinal chemistry. His research includes a 2022 study, where he explored how capsaicin boosts mupirocin’s efficacy against Staphylococcus aureus by inhibiting the MdeA efflux pump. ๐Ÿงช๐Ÿ”ฌ In 2013, Dr. Kalia identified novel inhibitors for the multidrug-resistant efflux pump Rv1258c in Mycobacterium tuberculosis. ๐Ÿฆ ๐Ÿ” His 2010 study highlighted how piperine enhances rifampicin’s protective efficacy against Mycobacterium tuberculosis infection, showcasing its immunomodulatory activity. ๐ŸŒฟ๐Ÿ›ก๏ธ His work underscores a commitment to advancing antimicrobial and immunomodulatory therapies. ๐Ÿ‘ฉโ€๐Ÿ”ฌ๐Ÿ‘จโ€๐Ÿ”ฌ

๐Ÿ“„ Publications Top Notes

Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion ofย Staphylococcus aureus

Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection

Piperine analogs as potent Staphylococcus aureus NorA efflux pump inhibitors

Sulfur rich 2-mercaptobenzothiazole and 1, 2, 3-triazole conjugates as novel antitubercular agents

Piperine as an inhibitor of the MdeA efflux pump ofย Staphylococcus aureus

Protective efficacy of piperine against Mycobacterium tuberculosis

Antimicrobial and Antimycobacterial Activities of Methyl Caffeate Isolated fromย Solanum torvumย Swartz. Fruit

Targeting theย Mycobacterium ulceransย cytochromeย bc1:aa3ย for the treatment of Buruli ulcer

Boeravinone B, A Novel Dual Inhibitor of NorA Bacterial Efflux Pump ofย Staphylococcus aureusย and Humanย P-Glycoprotein, Reduces the Biofilm Formation andย โ€ฆ

Dual inhibition of the terminal oxidases eradicates antibioticโ€tolerantย Mycobacterium tuberculosis